Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

CYBN

Cybin (CYBN)

Cybin Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NEO:CYBN
DateTimeSourceHeadlineSymbolCompany
24/03/202223:18InvestorsHub NewsWireCybin-Sponsored Feasibility Study Using Kernel Flow Technology Currently Recruiting ParticipantsNEO:CYBNCybin Inc
17/03/202200:40InvestorsHub NewsWireCybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022NEO:CYBNCybin Inc
19/02/202200:37InvestorsHub NewsWireCybin Announces Additional Adelia Milestone AchievementNEO:CYBNCybin Inc
16/02/202200:29InvestorsHub NewsWireThe Chopra Foundation Announces Partnership with Cybin Inc. to Increase Education and Awareness of the Potential Use of Psychedelics in Supporting Well-Being and Mental HealthNEO:CYBNCybin Inc
10/02/202200:36InvestorsHub NewsWireCybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety DisordersNEO:CYBNCybin Inc
28/01/202200:35InvestorsHub NewsWireCybin to Announce Third Quarter Financial Results and Business Update on February 10, 2022NEO:CYBNCybin Inc
12/01/202202:08InvestorsHub NewsWireInstitutional Review Board Grants Approval for Cybin-Sponsored Feasibility Study Using Kernel Flow Technology to Measure Psychedelic Effects on the BrainNEO:CYBNCybin Inc
23/12/202100:21InvestorsHub NewsWireCybin Provides 2021 Year End SummaryNEO:CYBNCybin Inc
22/12/202100:57InvestorsHub NewsWireCybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect ConferenceNEO:CYBNCybin Inc
16/12/202101:44InvestorsHub NewsWireCybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety DisordersNEO:CYBNCybin Inc
09/12/202103:11InvestorsHub NewsWireCybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use DisorderNEO:CYBNCybin Inc
01/12/202102:07InvestorsHub NewsWireCybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related DistressNEO:CYBNCybin Inc
16/11/202100:31InvestorsHub NewsWireCybin Inc. Reports its Second Quarter Financial Results and Recent Business HighlightsNEO:CYBNCybin Inc
09/11/202100:29InvestorsHub NewsWireCybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental HealthNEO:CYBNCybin Inc
04/11/202122:46InvestorsHub NewsWireCybin Granted DEA Schedule I Manufacturing LicenseNEO:CYBNCybin Inc
03/11/202100:13InvestorsHub NewsWireCybin Hosting Research and Development Briefing on November 8, 2021NEO:CYBNCybin Inc
27/10/202100:44InvestorsHub NewsWireCybin Announces FDA Investigational New Drug Authorization of Cybin's Sponsored Feasibility Study Using Kernel Flow TechnologyNEO:CYBNCybin Inc
13/10/202100:23InvestorsHub NewsWireCybin Files an International Patent Application Covering Psychedelic Delivery MethodsNEO:CYBNCybin Inc
20/08/202100:34InvestorsHub NewsWireCybin Files Two Additional International Patent Applications in Support of the Company's Research Phase ProgramsNEO:CYBNCybin Inc
05/08/202100:00InvestorsHub NewsWireCybin to Commence Trading on the NYSE American on August 5NEO:CYBNCybin Inc
22/07/202123:41InvestorsHub NewsWireCybin Announces Conditional Listing Approval from NYSE AmericanNEO:CYBNCybin Inc
13/07/202122:23InvestorsHub NewsWireCybin Files its 13th Patent Application and Announces Digital Therapeutics StrategyNEO:CYBNCybin Inc
06/07/202121:21InvestorsHub NewsWireCybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of ExcellenceNEO:CYBNCybin Inc
24/06/202123:42InvestorsHub NewsWireCybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory BoardNEO:CYBNCybin Inc
22/06/202123:39InvestorsHub NewsWireCybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule StudyNEO:CYBNCybin Inc
17/06/202100:44InvestorsHub NewsWireCybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004NEO:CYBNCybin Inc
08/06/202121:16InvestorsHub NewsWireCybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout andNEO:CYBNCybin Inc
 Showing the most relevant articles for your search:NEO:CYBN